ALA now ~5x the market cap of CHM.
It makes no sense!
ALA are still at the pre-clinical stage. IMU have their own CD19 directed off-the-shelf cell therapy, close to starting a registrational trial. They don't have an urgent need for ALA.
Meanwhile CHM have multiple CAR-T and NK cells in clinical trials, with more novel targets in the pipeline.
Why such a huge mismatch? I know CHM is far more expensive to run. But that is the nature of clinical stage cell therapy companies. Is the value of ALA all down to it's manufacturing IP?
CHM-The only ASX listed CAR-T comp with 2/3 human trials, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |